Compositions and methods for treating an inflammatory disease or disorder

Abstract

The invention relates to compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. In certain aspects, the invention relates to immunogenic compositions (e.g., vaccines) to diminish the number or pathogenic effects of one or more bacteria associated with the development or progression of an inflammatory disease or disorder.

What is claimed is: 
     
         1 . A method of treating or preventing an inflammatory disease or disorder associated with a secretory antibody-bound bacteria in the microbiota of a subject in need thereof, the method comprising administering to the subject at least one therapy to diminish the number or pathogenic effects of a bacteria associated with an inflammatory disease or disorder, wherein the bacteria is a member of the  Erysipelotrichaceae  family. 
     
     
         2 . The method of  claim 1 , wherein the member of the  Erysipelotrichaceae  family is a species of  Allobaculum.    
     
     
         3 . The method of  claim 1 , wherein the at least one therapy is selected from the group consisting of a vaccine, an antibiotic and a passive immunotherapy. 
     
     
         4 . The method of  claim 3 , wherein the vaccine comprises a heat-killed or an inactivated bacterium. 
     
     
         5 . The method of  claim 3 , wherein the vaccine comprises an adjuvant. 
     
     
         6 . The method of  claim 3 , wherein the vaccine is administered orally to the subject. 
     
     
         7 . The method of  claim 5 , wherein the adjuvant is selected from the group consisting of RIBI, KLH peptide, cholera toxin,  E. coli  heat-labile toxin,  E. coli  enterotoxin,  salmonella  toxin, AB5 toxin, nanoparticle-based adjuvant, calcium phosphate, liposomes, virosomes, cochleates, eurocine, archaeal lipids, ISCOMS, microparticles, monophosphoryl lipid (MPL), N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), Detox, AS04, AS02, AS01, OM-174, OM-triacyl, oligonucleotides, double-stranded RNA, pathogen-associated molecular patterns (PAMPs), TLR ligands, chitosan, a-galactosylceramide, small-molecule immune potentiators (SMIPs), a cytokine, a chemokine, DC Choi, PLA (polylactic acid) microparticles, PLG (poly[lactide-co-glycolide]) microparticles, Poly(DL-lactide-co-glycolide) microparticles, polystyrene (latex) microparticles, proteosomes, and 3′,5′-Cyclic diguanylic acid (c-di-GMP). 
     
     
         8 . The method of  claim 5 , wherein the adjuvant is selected from the group consisting of cholera toxin,  E. coli  heat-labile toxin,  E. coli  enterotoxin, or  salmonella  toxin. 
     
     
         9 . An immunogenic composition for treating or preventing an inflammatory disease or disorder, the composition comprising a vaccine to diminish the number or pathogenic effects of a bacteria associated with an inflammatory disease or disorder, wherein the bacteria is a member of the  Erysipelotrichaceae  family. 
     
     
         10 . The immunogenic composition of  claim 9 , wherein the member of the  Erysipelotrichaceae  family is a species of  Allobaculum.    
     
     
         11 . The immunogenic composition of  claim 9 , wherein the vaccine comprises a heat-killed or an inactivated bacterium. 
     
     
         12 . The immunogenic composition of  claim 9 , wherein the vaccine comprises an adjuvant. 
     
     
         13 . The immunogenic composition of  claim 12 , wherein the adjuvant is selected from the group consisting of RIBI, KLH peptide, cholera toxin,  E. coli  heat-labile toxin,  E. coli  enterotoxin,  salmonella  toxin, AB5 toxin, nanoparticle-based adjuvant, calcium phosphate, liposomes, virosomes, cochleates, eurocine, archaeal lipids, ISCOMS, microparticles, monophosphoryl lipid (MPL), N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), Detox, AS04, AS02, AS01, OM-174, OM-triacyl, oligonucleotides, double-stranded RNA, pathogen-associated molecular patterns (PAMPs), TLR ligands, chitosan, a-galactosylceramide, small-molecule immune potentiators (SMIPs), a cytokine, a chemokine, DC Choi, PLA (polylactic acid) microparticles, PLG (poly[lactide-co-glycolide]) microparticles, Poly(DL-lactide-co-glycolide) microparticles, polystyrene (latex) microparticles, proteosomes, and 3′,5′-Cyclic diguanylic acid (c-di-GMP). 
     
     
         14 . The method of  claim 12 , wherein the adjuvant is selected from the group consisting of cholera toxin,  E. coli  heat-labile toxin,  E. coli  enterotoxin, or  salmonella  toxin. 
     
     
         15 . A method of treating inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject non-colitogenic bacteria, wherein the non-colitogenic bacteria do not contribute to the development or progression of IBD in the subject, and wherein the subject has been diagnosed with IBD via detection of secretory antibody-bound colitogenic bacteria that do contribute to the development or progression of IBD, wherein the non-colitogenic bacteria is  Akkermansia mucimphila  while the colitogenic bacteria is a member of the  Erysipelotrichaceae  family. 
     
     
         16 . The method of  claim 15 , wherein the member of the  Erysipelotrichaceae  family is a species of  Allobaculum.    
     
     
         17 . The method of  claim 15 , further comprising administering to the subject at least one therapy to diminish the number or pathogenic effects of the colitogenic bacteria present in the subject. 
     
     
         18 . The method of  claim 17 , wherein the at least one therapy is selected from the group consisting of a vaccine, an antibiotic, and a passive immunotherapy. 
     
     
         19 . The method of  claim 18 , wherein the at least one therapy is a vaccine.